Biomarkers

The prospect of immunotherapy for combating Alzheimer’s disease

The prospect of immunotherapy for combating Alzheimer’s disease

Alzheimer’s disease is a progressive incurable neurodegenerative disorder that often leads to dementia, loss of motor function and cognitive decline. Current treatment options for Alzheimer’s disease slow the progression of neuronal degeneration and maximise function as far as possible, however, no treatment to date has managed to alter the disease process within the brain.

Immune checkpoint inhibitors and MDSCs

Immune checkpoint inhibitors and MDSCs

The development of immune checkpoint inhibitors (ICIs) targeting lymphoid cells has remarkedly transformed therapeutic approaches for the treatment of cancer. However, response rates to T cell checkpoint inhibitors vary between individuals with some patients showing minimal to no clinical benefit. In these patients, resistance to this immunotherapy may be partly attributed to myeloid- derived suppressor cells (MDSCs), a heterogeneous population of myeloid progenitors and immature myeloid cells that function as immune suppressors.